1 From the Department of Hematology/Oncology, Children's Hospital, Oakland, California
Newborn screening for sickle cell disease has been recommended as a method of decreasing patient mortality. However, its effectiveness in accomplishing this has not been reliably measured. To help determine the effectiveness, 10 years of experience in newborn screening have been summarized. The effects of early patient enrollment in a comprehensive treatment program on long-term morbidity and mortality are reported. From 1975 to 1985, 84,663 newborns were screened regardless of race or ethnic background. Bart's hemoglobin was present in 5%, hemoglobin AS in 2.6%, and hemoglobin AC in 0.75%. Excluding Bart's, approximately 3.6% of all newborns were carriers for hemoglobinopathy. Sickle cell disease occurred in 1:951 births (58 hemoglobin SS, 25 hemoglobin FSC, three hemoglobin S-
+-thalassemia, and three hemoglobin S-
°-thalassemia). In addition, one in every 4,233 newborns had a clinically significant thalassemia syndrome (eight hemoglobin FE, ten hemoglobin F only, two hemoglobin H). Compared with other newborn screening programs in California, (congenital hypothyroidism, 1:3,849; phenylketonuria 1:22,474, galactosemia 1:74,103), hemoglobinopathies are the most prevalent congenital disease. Eighty-one newborns with sickle cell disease were followed for 7.2 years. Patients experienced 513 hospitalizations, including 13 episodes of sepsis with or without meningitis and ten acute sequestration crises. The overall mortality rate for patients with sickle cell anemia diagnosed in the newborn period was 1.8%. In comparison, the clinical course of 64 patients with sickle cell anemia diagnosed after 3 months of age and followed for an average of 9.4 years was analyzed. Five of these patients died. In two of these, sickle cell anemia was diagnosed at the time of the death. Overall mortality rate in this group was 8%. In summary, the data indicate that newborn screening, when coupled with extensive follow-up and education, will significantly decrease patient mortality.
Key Words: newborn screening sickle cell disease sepsis anemia hemoglobinopathy
Submitted on November 5, 1987
Accepted on January 4, 1988
This article has been cited by other articles:
![]() |
I. Roberts and M. de Montalembert Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe Haematologica, July 1, 2007; 92(7): 865 - 871. [Full Text] [PDF] |
||||
![]() |
M. W. Crawford, S. Galton, and M. Abdelhaleem REPLY Can J Anesth, June 1, 2006; 53(6): 632 - 633. [Full Text] [PDF] |
||||
![]() |
M. W. Crawford, S. Galton, and M. Abdelhaleem Preoperative screening for sickle cell disease in children: clinical implications: [Depistage preoperatoire de la drepanocytose chez les enfants : implications cliniques] Can J Anesth, December 1, 2005; 52(10): 1058 - 1063. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. T. Quinn, Z. R. Rogers, and G. R. Buchanan Survival of children with sickle cell disease Blood, June 1, 2004; 103(11): 4023 - 4027. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Claster and E. P Vichinsky Managing sickle cell disease BMJ, November 15, 2003; 327(7424): 1151 - 1155. [Full Text] [PDF] |
||||
![]() |
M. C. Rahimy, A. Gangbo, G. Ahouignan, R. Adjou, C. Deguenon, S. Goussanou, and E. Alihonou Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting Blood, August 1, 2003; 102(3): 834 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
Section on Hematology/Oncology and Committee on Ge Health Supervision for Children with Sickle Cell Disease Pediatrics, March 1, 2002; 109(3): 526 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Campbell, J. S. Henthorn, and S. C. Davies Evaluation of Cation-Exchange HPLC Compared with Isoelectric Focusing for Neonatal Hemoglobinopathy Screening Clin. Chem., July 1, 1999; 45(7): 969 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Steinberg Management of Sickle Cell Disease N. Engl. J. Med., April 1, 1999; 340(13): 1021 - 1030. [Full Text] [PDF] |
||||
![]() |
N. A. Holtzman, P. D. Murphy, M. S. Watson, and P. A. Barr Predictive Genetic Testing: From Basic Research to Clinical Practice Science, October 24, 1997; 278(5338): 602 - 605. [Abstract] [Full Text] |
||||
![]() |
B. Houser, H. M. Plawecki, J. Carr, M. A. Smith, and J. A. Plawecki A Holistic Approach to Vaso-Occlusive Pain Crisis in Children With Sickle Cell Disease J Holist Nurs, March 1, 1992; 10(1): 62 - 75. [Abstract] [PDF] |
||||